Eli Lilly Supercharges Lebanon Site with $9B for Weight-Loss Drugs

LEBANON, Ind. (Day.News) — Eli Lilly and Company, the Indianapolis-based pharmaceutical giant, announced in May 2024 it is expanding its Boone County manufacturing project from $3.7 billion to $9 billion, marking the largest investment in the company's 150-year history. The upgraded facilities in the LEAP Lebanon Innovation and Research District will boost production of active pharmaceutical ingredients for Mounjaro and Zepbound, Lilly's top-selling treatments for diabetes and obesity. CEO Dave Ricks hailed the project during announcements, noting it addresses surging global demand amid supply shortages.

Ground was broken on the site near Lebanon last year, with initial production slated to begin by the end of 2026 and capacity scaling through 2028. The expansion builds on a 2022 commitment of $2.1 billion for two adjacent manufacturing plants in the same district, which are designed for active ingredients and advanced therapies targeting Alzheimer's, cancer, and genetic medicines. Pending local zoning approvals, the sites are expected to create 500 direct high-paying jobs at Lilly, plus 1,500 construction positions and thousands of indirect roles through partnerships with the Indiana Economic Development Corp.

Boone County's LEAP district, a planned tech and manufacturing hub, has drawn praise from state leaders including Gov. Eric Holcomb, who hosted Lilly executives at the Governor's Residence for the initial 2022 reveal. Lilly, which employs over 3,700 manufacturing workers across Indiana, is reinforcing its Hoosier roots while responding to explosive growth in its weight-loss drug portfolio. The investment arrives as Mounjaro and Zepbound generate billions in revenue, cementing Indiana's status as a nexus for life-saving innovation.